BMY — BRISTOL MYERS SQUIBB CO catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

11 verified catalyst event(s) for BRISTOL MYERS SQUIBB CO (ticker BMY). Each is linked to its official source. Verified as of 2026-08-06.

Next verified catalyst

2026-09-05 — A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-09-05 in 30d ESTIMATED	READOUT A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors Phase 1/2 · Advanced Solid Tumors	BMY BRISTOL MYERS SQUIBB CO	BMS-986490, Bevacizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-09-30 in 2mo ESTIMATED	READOUT A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced S Phase 1/2 · Advanced Solid Tumors	BMY BRISTOL MYERS SQUIBB CO	BMS-986449, Nivolumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-10-06 in 2mo ESTIMATED	READOUT A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Part Phase 3 · Idiopathic Pulmonary Fibrosis	BMY BRISTOL MYERS SQUIBB CO	BMS-986278, BMS-986278 Placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-10-12 in 2mo ESTIMATED	READOUT A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-98634 Phase 1/2 · Multiple Myeloma	BMY BRISTOL MYERS SQUIBB CO	CC-92480, Tazemetostat, BMS-986158, Tram	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-10-19 in 2mo ESTIMATED	READOUT A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Plac Phase 3 · Systemic Lupus Erythematosus	BMY BRISTOL MYERS SQUIBB CO	Deucravacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-10-19 in 2mo ESTIMATED	READOUT A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Com Phase 3 · Systemic Lupus Erythematosus	BMY BRISTOL MYERS SQUIBB CO	Deucravacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11-01 in 3mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Phase 3 · Bipolar-I Disorder With Mania or Mania With Mixed Features	BMY BRISTOL MYERS SQUIBB CO	KarXT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11-02 in 3mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Phase 3 · Bipolar Disorder Type I With Mania or Mania With Mixed Features	BMY BRISTOL MYERS SQUIBB CO	KarXT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11-18 in 3mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Ac Phase 3 · Sjögren's Syndrome	BMY BRISTOL MYERS SQUIBB CO	Deucravacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12-01 in 4mo ESTIMATED	READOUT A Study to Continue the Administration of Deucravacitinib in Participants With S Phase 4 · Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)	BMY BRISTOL MYERS SQUIBB CO	BMS-986165	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12-14 in 4mo ESTIMATED	READOUT Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Phase 2 · Heart Failure	BMY BRISTOL MYERS SQUIBB CO	BMS-986435	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change